Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX® (Immune mobilizing monoclonal TCRs Against X disease) platform, we are developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q2 2024 · $75.4MThe company’s own SEC segment disclosure.
- Sale Of Therapies$75.3M100%
- Collaboration$53.0K0%
Immunocore Holdings plc (IMCR) reported revenue of $107M in Q1 2026 (quarter ended Mar 31, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 100% and net income of $13M (12% of revenue). For the full year FY2025, revenue was $400M (+29% year on year) and net income −$36M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was Sale Of Therapies at $75M, 100% of the disclosed total, well ahead of Collaboration at 0.1%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.